Prof Michael Barnett, Director Sydney Neuroimaging Analysis Centre and Professor of Neurology, University of Sydney, joins JNNP's Podcast Editor, Colin Mahoney, to discuss how the use of Alemtuzumab may have longer-term impacts on improving one of the most commonly involved neurological pathways, the visual system, in multiple sclerosis (MS). Prof Barnett discusses his team's results after following up patients with highly active MS for 24 months, using multifocal visual evoked potentials and advanced neuroimaging. He also talks about what this means for future remyelination strategies. Related paper: https://jnnp.bmj.com/content/92/12/1319